1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Novel Therapies Vital to Counter the Challenge from Generics in the U.S. Rheumatoid Arthritis Market

The unmet need for a convenient and safe rheumatoid arthritis (RA) treatment option without adverse side effects has set the stage for a spate of drug launches in the near future.

 
PRLog - Sep. 28, 2011 - SAN ANTONIO -- Frost & Sullivan: Novel Therapies Vital to Counter the Challenge from Generics in the U.S. Rheumatoid Arthritis Market

Rise in incidence of rheumatoid arthritis from 2.4 million in 2010 to 2.6 million in 2017 encourages development of new drugs

MOUNTAIN VIEW, Calif. – Sept. 28, 2011, 2011 – The unmet need for a convenient and safe rheumatoid arthritis (RA) treatment option without adverse side effects has set the stage for a spate of drug launches in the near future. As a result of this demand, some of the current pipeline drugs have the potential to be blockbusters, especially the oral treatments in late-stage development.

In 2010, the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) revised the 1987 classification criteria for RA to enable early detection. The new classification facilitates diagnosing RA patients and thereby, gives a boost to the treatment market.

New analysis from Frost & Sullivan’s (http://www.frost.com) U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments research finds that the market for RA (biologics and new treatments) earned revenues of $5.78 billion in 2010. This is expected to increase to $8.34 billion in 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, title, telephone number, company email address, company Web site, city, state and country.

The first-line of biologic agents, after methotrexate, is Enbrel and Humira; Remicade, Simponi, and Cimzia are additional anti-tumor necrosis factor (TNF) options. If patients experience TNF failure, physicians then will either change to a second anti-TNF or switch classes to Orencia, Actemra or Rituxan.

Compounds in the late stages of development include CP-690,550 and fostamatinib disodium. CP-690,550 (tasocitinib) is a Janus kinases (JAK) 1/3 inhibitor, which is expected to be the first oral compound to reach the RA market for disease-modifying antirheumatic drugs (DMARDs) inadequate responders (IR). As tasocitinib is being developed as an oral medication, it has the potential to be used ahead of TNF antagonists in the RA treatment paradigm.

R788 is also being evaluated as an oral twice-a-day treatment, as it can be an improvement on the expensive TNF blockers that are delivered subcutaneously or intravenously and have side effects.

Small molecules such as Pfizer’s CP-690,550 can have a big impact on the market if they demonstrate positive safety and efficacy data due to the convenience and low cost of oral therapy.

“With the number of biologics on the market and in development for RA, the RA treatment market is becoming crowded,” said Frost & Sullivan Industry Manager Jennifer Brice. “Biologics entering this market must be able to show efficacy and safety data that is comparable, if not superior, to TNF blockers to gain any market share.”

Currently, many biologics such as TNF antagonists are associated with severe adverse events such as infections and lymphoma. Safety concerns and the annual cost of RA treatment, which can vary from $10,000 to $20,000, can restrain patients–especially uninsured ones–from opting for biologics.

With the patent of the first-line biologic, Enbrel, due to expire in 2012, the entry of biosimilars could be a game changer. Although they can increase adoption rates and availability, these low-priced generics could reduce revenue generation rates.

If adequate reimbursements are not available, patients may choose biosimilars over expensive novel therapies, which will slow down the market’s growth rate. Tight budgets from insurance companies will further restrict the use of novel therapies and encourage generics.

“Biosimilars are expected to influence the U.S. market in the next three years to four years,” said Brice. “To fight back the challenge from these generics, pharmaceutical and biotech companies need to continue to address unmet needs in the treatment of RA by developing novel medications.”

U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: Rheumatoid Arthritis Therapeutics Market in Australia, Rheumatoid Arthritis Therapeutics Market in Japan, Rheumatoid Arthritis Therapeutics Market in India, and Rheumatoid Arthritis Therapeutics Market in China. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
N96E

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com

http://www.frost.com

# # #

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

--- End ---

Click to Share

Contact Email:
***@frost.com Email Verified
Source:Frost & Sullivan
Phone:2104778481
Zip:78229
City/Town:San Antonio - Texas - United States
Industry:Health, Medical, Biotech
Tags:arthritis, pharma, therapies, generic, rheumatoid arthritis, drug, treatment, drug launch, blockbuster, acr, EULAR
Shortcut:prlog.org/11677056
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share